Brainstorm Health: Tech and the Measles flare-up, Cell Therapy Coverage, Hospital Readmission

Brainstorm Health: Tech and the Measles flare-up, Cell Therapy Coverage, Hospital Readmission

A continuous measles outbreak in the Pacific Northwest and past is currently putting weight on some of Silicon Valley’s greatest players, including Facebook and Google, to make a move to expose false data and paranoid notions with respect to vaccines.

California Rep. Adam Schiff on Thursday sent letters to Facebook CEO Mark Zuckerberg and Google CEO Sundar Pichai requesting data on what the companies are doing to pack down on the proliferation of misinformation. Against antibody paranoid notions and deceiving articles about inoculation have been routinely spread by means of the separate organizations’ platforms.

“As a Member of Congress who is deeply concerned about declining vaccination rates, I am requesting additional information on the steps that you currently take to provide medically accurate information on vaccinations to your users, and to encourage you to consider additional steps you can take to address this growing problem,” wrote Schiff in his letter.

Schiff also praised the action taken by another tech giant to fight the current misinformation trend. “I was pleased to see YouTube’s recent announcement that it will no longer recommend videos that violate its community guidelines, such as conspiracy theories or medically inaccurate videos, and encourage further action to be taken related to vaccine misinformation,” he wrote.

Facebook is allegedly taking a shot at ventures to attempt and check this general health disaster; Congress is slated to hold hearings on the issue toward the beginning of March.

We’ll be off on Monday for the long weekend. Peruse on for the day’s news, and see you back in your inbox on Tuesday the nineteenth.

Advanced HEALTH

The government is going to cover cell therapies. The Centers for Medicare and Medicaid Services (CMS) declared on Friday that new cell treatments from medication monsters Novartis and Gilead—the first of their sort, medicines that re-engineer patients’ cells to battle cancer growth but on the other hand are fantastically expensive—will be secured under an exploratory installment plan by general society organization. The purported CAR-T therapies would be secured under the proposed standard, which would likewise include surveying whether these cutting edge therapeutic bang for the buck (the list prices run between $373,000 and $475,000, though the government would pay a far lower price).

THE BIG PICTURE

Can a longer hospital stay be healthy? A new study from the University of Wisconsin researchers finds that leaving the hospital early (and against medical advice) can double the risk of readmission within 30 days. The study also highlights the specific conditions that are most likely to lead to an unadvised discharge—they include alcohol and substance abuse disorders, skin infections, and complications from diabetes, according to Reuters.

Share this post